Modified lipoproteins as biomarkers of cardiovascular risk in diabetes mellitus;Lipoproteínas modificadas como marcadores de riesgo cardiovascular en la diabetes mellitus

Endocrinologia y Nutricion

Volumn 60, Issue 9, 2013, Pages 518-528

  Sánchez Quesada, José Luis ^a   Pérez, Antonio ^b,c  

^a Centro Cochrane Iberoamericano Instituto de Investigación Biomédica Sant Pau   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Atherosclerosis; Biomarkers; Cardiovascular risk; Diabetes mellitus; Modified lipoproteins

Indexed keywords

LIPOPROTEIN; MODIFIED LIPOPROTEIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DIABETES MELLITUS; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SHORT SURVEY; BLOOD; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; HUMAN; METABOLISM;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; HUMANS; LIPOPROTEINS, LDL; RISK ASSESSMENT;

EID: 84887607622     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/j.endonu.2012.12.007     Document Type: Short Survey

References (120)

1. Giacco F., Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010, 107:1058-1070.
2. Mooradian A.D. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2009, 5:150-159.
3. Levitan I., Volkov S., Subbaiah P.V. Oxidized LDL: Diversity, patterns of recognition, and pathophysiology. Antioxid Redox Signal 2010, 13:39-75.
4. Fraley A.E., Tsimikas S. Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease. Curr Opin Lipidol 2006, 17:502-509.
5. Alberti K.G., Zimmet P., Shaw J. Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006, 23:469-480.
6. Farmer J.A. Diabetic dyslipidemia and atherosclerosis: Evidence from clinical trials. Curr Diab Rep 2008, 8:71-77.
7. Sahade V., França S., Badaró R., Fernando Adán L. Obesity and postprandial lipemia in adolescents: Risk factors for cardiovascular disease. Endocrinol Nutr 2012, 59:131-139.
8. Wagner Fahlin A.M., Sánchez Quesada J.L., Pérez Pérez A. Diabetes mellitus y lipemia posprandial. Endocrinol Nutr 2000, 47:311-321.
9. Vergès B. Abnormal hepatic apolipoprotein B metabolism in type 2 diabetes. Atherosclerosis 2010, 211:353-360.
10. Ascaso J.F. Advances in cholesterol-lowering interventions. Endocrinol Nutr 2010, 57:210-219.
11. Escolà-Gil J.C., Rotllan N., Julve J., Blanco-Vaca F. In vivo macrophage-specific RCT and antioxidant and antiinflammatory HDL activity measurements: New tools for predicting HDL atheroprotection. Atherosclerosis 2009, 206:321-327.
12. Kontush A., Chapman M.J. Why is HDL functionally deficient in type 2 diabetes?. Curr Diab Rep 2008, 8:51-59.
13. Chapman M.J., Guérin M., Bruckert E. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Eur Heart J 1998, 19(Suppl A):A24-A30.
14. Cerami A., Vlassara H., Brownlee M. Role of advanced glycosylation products in complications of diabetes. Diabetes Care 1988, 11(Suppl 1):73-79.
15. Curtiss L.K., Witztum J.L. Plasma apolipoproteins AI, AII, B, CI, and E are glucosylated in hyperglycemic diabetic subjects. Diabetes 1985, 34:452-461.
16. Wang X., Bucala R., Milne R. Epitopes close to the apolipoprotein B low density lipoprotein receptor-binding site are modified by advanced glycation end products. Proc Natl Acad Sci U S A 1998, 95:7643-7647.
17. Younis N., Charlton-Menys V., Sharma R., Soran H., Durrington P.N. Glycation of LDL in non-diabetic people: Small dense LDL is preferentially glycated both in vivo and in vitro. Atherosclerosis 2009, 202:162-168.
18. Brownlee M., Cerami A., Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988, 318:1315-1321.
19. Lopes-Virella M.F., Klein R.L., Virella G. Modification of lipoproteins in diabetes. Diabetes Metab Rev 1996, 12:69-90.
20. Virella G., Atchley D., Koskinen S., Zheng D., Lopes-Virella M.F. Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol 2002, 105:81-92.
21. Isoda K., Folco E., Marwali M.R., Ohsuzu F., Libby P. Glycated LDL increases monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated chemotaxis. Atherosclerosis 2008, 198:307-312.
22. Hodgkinson C.P., Laxton R.C., Patel K., Ye S. Advanced glycation end-product of low density lipoprotein activates the toll-like 4 receptor pathway implications for diabetic atherosclerosis. Arterioscler Thromb Vasc Biol 2008, 28:2275-2281.
23. Younis N., Sharma R., Soran H., Charlton-Menys V., Elseweidy M., Durrington P.N. Glycation as an atherogenic modification of LDL. Curr Opin Lipidol 2008, 19:378-384.
24. Rabbani N., Thornalley P.J. Glyoxalase in diabetes, obesity and related disorders. Semin Cell Dev Biol 2011, 22:309-317.
25. Rabbani N., Chittari M.V., Bodmer C.W., Zehnder D., Ceriello A., Thornalley P.J. Increased glycation and oxidative damage to apolipoprotein B100 of LDL cholesterol in patients with type 2 diabetes and effect of metformin. Diabetes 2010, 59:1038-1045.
26. Rabbani N., Godfrey L., Xue M., Shaheen F., Geoffrion M., Milne R., et al. Glycation of LDL by methylglyoxal increases arterial atherogenicity: A possible contributor to increased risk of cardiovascular disease in diabetes. Diabetes 2011, 60:1973-1980.
27. Brownlee M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 2005, 54:1615-1625.
28. Steinberg D. The LDL modification hypothesis of atherogenesis: An update. J Lipid Res 2009, 50:S376-S381.
29. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989, 320:915-924.
30. Navab M., Berliner J.A., Watson A.D., Hama S.Y., Territo M.C., Lusis A.J., et al. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 1996, 16:831-842.
31. Stary H.C. Natural history and histological classification of atherosclerotic lesions: An update. Arterioscler Thromb Vasc Biol 2000, 20:1177-1178.
32. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999, 340:115-126.
33. Navab M., Ananthramaiah G.M., Reddy S.T., van Lenten B.J., Ansell B.J., Fonarow G.C., et al. The oxidation hypothesis of atherogenesis: The role of oxidized phospholipids and HDL. J Lipid Res 2004, 45:993-1007.
34. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol 1995, 57:791-804.
35. Sánchez-Quesada J.L., Villegas S. Modified forms of LDL in plasma. Atherogenesis 2011, 447-472. InTech, Rijeka, Croatia. S. Parthasarathy (Ed.).
36. Oörni K., Kovanen P.T. Lipoprotein modification by secretory phospholipase A(2) enzymes contributes to the initiation and progression of atherosclerosis. Curr Opin Lipidol 2009, 20:421-427.
37. Katsuda S., Coltrera M.D., Ross R., Gown A.M. Human atherosclerosis. IV. Immunocytochemical analysis of cell activation and proliferation in lesions of young adults. Am J Pathol 1993, 142:1787-1793.
38. Pentikäinen M.O., Oörni K., Ala-Korpela M., Kovanen P.T. Modified LDL - trigger of atherosclerosis and inflammation in the arterial intima. J Intern Med 2000, 247:359-370.
39. Williams K.J., Tabas I. Lipoprotein retention--and clues for atheroma regression. Arterioscler Thromb Vasc Biol 2005, 25:1536-1540.
40. Fenske D., Dersch K., Lux C., Zipse L., Suriyaphol P., Dragneva Y., et al. Enzymatically hydrolyzed low-density lipoprotein modulates inflammatory responses in endothelial cells. Thromb Haemost 2008, 100:1146-1154.
41. Klouche M., Rose-John S., Schmiedt W., Bhakdi S. Enzymatically degraded, nonoxidized LDL induces human vascular smooth muscle cell activation, foam cell transformation, and proliferation. Circulation 2000, 101:1799-1805.
42. Stary H.C. Composition and classification of human atherosclerotic lesions. Virchows Arch A Pathol Anat Histopathol 1992, 421:277-290.
43. Williams K.J., Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol 1998, 9:471-474.
44. Tabas I. Nonoxidative modifications of lipoproteins in atherogenesis. Annu Rev Nutr 1999, 19:123-139.
45. Steinberg D., Witztum J.L. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis?. Circulation 2002, 105:2107-2111.
46. Witztum J.L., Steinberg D. The oxidative modification hypothesis of atherosclerosis: Does it hold for humans?. Trends Cardiovasc Med 2001, 11:93-102.
47. Bhakdi S., Lackner K.J., Han S.R., Torzewski M., Husmann M. Beyond cholesterol: The enigma of atherosclerosis revisited. Thromb Haemost 2004, 91:639-645.
48. Apostolov E.O., Ray D., Savenka A.V., Shah S.V., Basnakian A.G. Chronic uremia stimulates LDL carbamylation and atherosclerosis. J Am Soc Nephrol 2010, 21:1852-1857.
49. Apostolov E.O., Shah S.V., Ok E., Basnakian A.G. Quantification of carbamylated LDL in human sera by a new sandwich ELISA. Clin Chem 2005, 51:719-728.
50. Tertov V.V., Sobenin I.A., Gabbasov Z.A., Popov E.G., Jaakkola O., Solakivi T., et al. Multiple-modified desialylated low density lipoproteins that cause intracellular lipid accumulation. Isolation, fractionation and characterization. Lab Invest 1992, 67:665-675.
51. Tertov V.V., Bittolo-Bon G., Sobenin I.A., Cazzolato G., Orekhov A.N., Avogaro P. Naturally occurring modified low density lipoproteins are similar if not identical: More electronegative and desialylated lipoprotein subfractions. Exp Mol Pathol 1995, 62:166-172.
52. Lagrost L., Florentin E., Guyard-Dangremont V., Athias A., Gandjini H., Lallemant C., et al. Evidence for nonesterified fatty acids as modulators of neutral lipid transfers in normolipidemic human plasma. Arterioscler Thromb Vasc Biol 1995, 15:1388-1396.
53. Benítez S., Camacho M., Arcelus R., Vila L., Bancells C., Ordóñez-Llanos J., et al. Increased lysophosphatidylcholine and non-esterified fatty acid content in LDL induces chemokine release in endothelial cells. Relationship with electronegative LDL. Atherosclerosis 2004, 177:299-305.
54. Gaubatz J.W., Gillard B.K., Massey J.B., Hoogeveen R.C., Huang M., Lloyd E.E., et al. Dynamics of dense electronegative low density lipoproteins and their preferential association with lipoprotein phospholipase A(2). J Lipid Res 2007, 48:348-357.
55. Lu M., Gantz D.L., Herscovitz H., Gursky O. Kinetic analysis of thermal stability of human low density lipoproteins: A model for LDL fusion in atherogenesis. J Lipid Res 2012, 53:2175-2185.
56. Phillips C., Owens D., Collins P., Tomkin G.H. Low density lipoprotein non-esterified fatty acids and lipoprotein lipase in diabetes. Atherosclerosis 2005, 181:109-114.
57. Sánchez-Quesada J.L., Benítez S., Pérez A., Wagner A.M., Rigla M., Carreras G., et al. The inflammatory properties of electronegative low-density lipoprotein from type 1 diabetic patients are related to increased platelet-activating factor acetylhydrolase activity. Diabetologia 2005, 48:2162-2169.
58. Benítez S., Pérez A., Sánchez-Quesada J.L., Wagner A.M., Rigla M., Arcelus R., et al. Electronegative low-density lipoprotein subfraction from type 2 diabetic subjects is proatherogenic and unrelated to glycemic control. Diabetes Metab Res Rev 2007, 23:26-34.
59. Sánchez-Quesada J.L., Benítez S., Ordóñez-Llanos J. Electronegative low-density lipoprotein. Curr Opin Lipidol 2004, 15:329-335.
60. Avogaro P., Bon G.B., Cazzolato G. Presence of a modified low density lipoprotein in humans. Arteriosclerosis 1988, 8:79-87.
61. Mello A.P., da Silva I.T., Abdalla D.S., Damasceno N.R. Electronegative low-density lipoprotein: Origin and impact on health and disease. Atherosclerosis 2011, 215:257-265.
62. Sánchez-Quesada J.L., Vinagre I., de Juan-Franco E., Sánchez-Hernández J., Blanco-Vaca F., Ordónez-Llanos J., et al. Effect of improving glycemic control in patients with type 2 diabetes mellitus on low-density lipoprotein size, electronegative low-density lipoprotein and lipoprotein-associated phospholipase A2 distribution. Am J Cardiol 2012, 110:67-71.
63. Sánchez-Quesada J.L., Estruch M., Benítez S., Ordóñez-Llanos J. Electronegative LDL: A useful biomarker of cardiovascular risk. Clin Lipidol 2012, 7:345-359.
64. Ishigaki Y., Oka Y., Katagiri H. Circulating oxidized LDL: A biomarker and a pathogenic factor. Curr Opin Lipidol 2009, 20:363-369.
65. Holvoet P., Mertens A., Verhamme P., Bogaerts K., Beyens G., Verhaeghe R., et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2001, 21:844-848.
66. Holvoet P., Collen D., van de Werf F. Malondialdehyde-modified LDL as a marker of acute coronary syndromes. JAMA 1999, 281:1718-1721.
67. Nishi K., Itabe H., Uno M., Kitazato K.T., Horiguchi H., Shinno K., et al. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol 2002, 22:1649-1654.
68. Tsimikas S. Oxidized low-density lipoprotein biomarkers in atherosclerosis. Curr Atheroscler Rep 2006, 8:55-61.
69. Uno M., Kitazato K.T., Nishi K., Itabe H., Nagahiro S. Raised plasma oxidised LDL in acute cerebral infarction. J Neurol Neurosurg Psychiatry 2003, 74:312-316.
70. Holvoet P., Perez G., Zhao Z., Brouwers E., Bernar H., Collen D. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Invest 1995, 95:2611-2619.
71. Itabe H., Yamamoto H., Imanaka T., Shimamura K., Uchiyama H., Kimura J., et al. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res 1996, 37:45-53.
72. Tsimikas S., Witztum J.L. Measuring circulating oxidized low-density lipoprotein to evaluate coronary risk. Circulation 2001, 103:1930-1932.
73. Cohen M.P., Lautenslager G., Shea E. Glycated LDL concentrations in non-diabetic and diabetic subjects measured with monoclonal antibodies reactive with glycated apolipoprotein B epitopes. Eur J Clin Chem Clin Biochem 1993, 31:707-713.
74. Virella G., Derrick M.B., Pate V., Chassereau C., Thorpe S.R., Lopes-Virella M.F. Development of capture assays for different modifications of human low-density lipoprotein. Clin Diagn Lab Immunol 2005, 12:68-75.
75. Holvoet P., Theilmeier G., Shivalkar B., Flameng W., Collen D. LDL hypercholesterolemia is associated with accumulation of oxidized LDL, atherosclerotic plaque growth, and compensatory vessel enlargement in coronary arteries of miniature pigs. Arterioscler Thromb Vasc Biol 1998, 18:415-422.
76. Tsimikas S., Clopton P., Brilakis E.S., Marcovina S.M., Khera A., Miller E.R., et al. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: Results from the Dallas Heart Study. Circulation 2009, 119:1711-1719.
77. Frostegård J., Wu R., Lemne C., Thulin T., Witztum J.L., de Faire U. Circulating oxidized low-density lipoprotein is increased in hypertension. Clin Sci (Lond) 2003, 105:615-620.
78. Holvoet P., Vanhaecke J., Janssens S., van de Werf F., Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998, 98:1487-1494.
79. Tsimikas S., Aikawa M., Miller Jr F.J., Miller E.R., Torzewski M., Lentz S.R., et al. Increased plasma oxidized phospholipid:apolipoprotein B-100 ratio with concomitant depletion of oxidized phospholipids from atherosclerotic lesions after dietary lipid-lowering: A potential biomarker of early atherosclerosis regression. Arterioscler Thromb Vasc Biol 2007, 27:175-181.
80. Tsimikas S., Kiechl S., Willeit J., Mayr M., Miller E.R., Kronenberg F., et al. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: Five-year prospective results from the Bruneck study. J Am Coll Cardiol 2006, 47:2219-2228.
81. Herder C., Baumert J., Zierer A., Roden M., Meisinger C., Karakas M., et al. Immunological and cardiometabolic risk factors in the prediction of type 2 diabetes and coronary events: MONICA/KORA Augsburg case-cohort study. PLoS One 2011, 6:e19852.
82. Wu T., Willett W.C., Rifai N., Shai I., Manson J.E., Rimm E.B. Is plasma oxidized low-density lipoprotein, measured with the widely used antibody 4E6, an independent predictor of coronary heart disease among U.S. men and women?. J Am Coll Cardiol 2006, 48:973-979.
83. Meisinger C., Baumert J., Khuseyinova N., Loewel H., Koenig W. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation 2005, 112:651-657.
84. Tsimikas S., Bergmark C., Beyer R.W., Patel R., Pattison J., Miller E., et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol 2003, 41:360-370.
85. Tsimikas S., Lau H.K., Han K.R., Shortal B., Miller E.R., Segev A., et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): Short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation 2004, 109:3164-3170.
86. Ehara S., Ueda M., Naruko T., Haze K., Itoh A., Otsuka M., et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001, 103:1955-1960.
87. Hoogeveen R.C., Ballantyne C.M., Bang H., Heiss G., Duncan B.B., Folsom A.R., et al. Circulating oxidised low-density lipoprotein and intercellular adhesion molecule-1 and risk of type 2 diabetes mellitus: The Atherosclerosis Risk in Communities Study. Diabetologia 2007, 50:36-42.
88. Lopes-Virella M.F., Hunt K.J., Baker N.L., Lachin J., Nathan D.M., Virella G. Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes. Diabetes 2011, 60:582-589.
89. Sánchez-Quesada J.L., Pérez A., Caixàs A., Rigla M., Payés A., Benítez S., et al. Effect of glycemic optimization on electronegative low-density lipoprotein in diabetes: Relation to nonenzymatic glycosylation and oxidative modification. J Clin Endocrinol Metab 2001, 86:3243-3249.
90. Zhang B., Kaneshi T., Ohta T., Saku K. Relation between insulin resistance and fast-migrating LDL subfraction as characterized by capillary isotachophoresis. J Lipid Res 2005, 46:2265-2277.
91. Nakhjavani M., Asgharani F., Khalilzadeh O., Esteghamati A., Ghaneei A., Morteza A., et al. Oxidized low-density lipoprotein is negatively correlated with lecithin-cholesterol acyltransferase activity in type 2 diabetes mellitus. Am J Med Sci 2011, 341:92-95.
92. Bastos A.S., Graves D.T., Loureiro A.P., Rossa Júnior C., Abdalla D.S., Faulin Tdo E., et al. Lipid peroxidation is associated with the severity of periodontal disease and local inflammatory markers in patients with type 2 diabetes. J Clin Endocrinol Metab 2012, 97:E1353-E1362.
93. Akanji A.O., Abdella N., Mojiminiyi O.A. Determinants of glycated LDL levels in nondiabetic and diabetic hyperlipidaemic patients in Kuwait. Clin Chim Acta 2002, 317:171-176.
94. Abe M., Maruyama N., Okada K., Matsumoto S., Matsumoto K., Soma M. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. J Atheroscler Thromb 2011, 18:1018-1028.
95. Sánchez-Quesada J.L., Otal-Entraigas C., Franco M., Jorba O., González-Sastre F., Blanco-Vaca F., et al. Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 1999, 84:655-659.
96. Zhang B., Matsunaga A., Rainwater D.L., Miura S., Noda K., Nishikawa H., et al. Effects of rosuvastatin on electronegative LDL as characterized by capillary isotachophoresis: The ROSARY Study. J Lipid Res 2009, 50:1832-1841.
97. Virella G., Lopes-Virella M.F. The pathogenic role of the adaptive immune response to modified LDL in diabetes. Front Endocrinol (Lausanne) 2012, 3:76.
98. Rizzo M., Berneis K., Koulouris S., Pastromas S., Rini G.B., Sakellariou D., et al. Should we measure routinely oxidised and atherogenic dense low-density lipoproteins in subjects with type 2 diabetes?. Int J Clin Pract 2010, 64:1632-1642.
99. Shimada K., Mokuno H., Matsunaga E., Miyazaki T., Sumiyoshi K., Kume A., et al. Predictive value of circulating oxidized LDL for cardiac events in type 2 diabetic patients with coronary artery disease. Diabetes Care 2004, 27:843-844.
100. Holvoet P., Harris T.B., Tracy R.P., Verhamme P., Newman A.B., Rubin S.M., et al. Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: Findings from the Health, Aging, and Body Composition study. Arterioscler Thromb Vasc Biol 2003, 23:1444-1448.
101. Hsu R.M., Devaraj S., Jialal I. Autoantibodies to oxidized low-density lipoprotein in patients with type 2 diabetes mellitus. Clin Chim Acta 2002, 317:145-150.
102. Lopes-Virella M.F., Hunt K.J., Baker N.L., Virella G., Moritz T. The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis 2012, 224:526-531.
103. Ujihara N., Sakka Y., Takeda M., Hirayama M., Ishii A., Tomonaga O., et al. Association between plasma oxidized low-density lipoprotein and diabetic nephropathy. Diabetes Res Clin Pract 2002, 58:109-114.
104. Gokulakrishnan K., Deepa R., Velmurugan K., Ravikumar R., Karkuzhali K., Mohan V. Oxidized low-density lipoprotein and intimal medial thickness in subjects with glucose intolerance: The Chennai Urban Rural Epidemiology Study-25. Metabolism 2007, 56:245-250.
105. Piarulli F., Lapolla A., Sartore G., Rossetti C., Bax G., Noale M., et al. Autoantibodies against oxidized LDLs and atherosclerosis in type 2 diabetes. Diabetes Care 2005, 28:653-657.
106. Brown W.V., Goldberg R.B., Lopes-Virella M., Reaven P. Reducing vascular disease risk in the type 2 diabetic patient. J Clin Lipidol 2011, 5:3-11.
107. Lopes-Virella M.F., Thorpe S.R., Derrick M.B., Chassereau C., Virella G. The immunogenicity of modified lipoproteins. Ann N Y Acad Sci 2005, 1043:367-378.
108. Lopes-Virella M.F., Virella G. Immune mechanisms in the pathogenesis of atherosclerosis. Adv Exp Med Biol 1991, 285:383-392.
109. Witztum J.L., Koschinsky T. Metabolic and immunological consequences of glycation of low density lipoproteins. Prog Clin Biol Res 1989, 304:219-234.
110. Tsimikas S., Palinski W., Witztum J.L. Circulating autoantibodies to oxidized LDL correlate with arterial accumulation and depletion of oxidized LDL in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2001, 21:95-100.
111. Korpinen E., Groop P.H., Akerblom H.K., Vaarala O. Immune response to glycated and oxidized LDL in IDDM patients with and without renal disease. Diabetes Care 1997, 20:1168-1171.
112. Oliveira J.A., Sevanian A., Rodrigues R.J., Apolinário E., Abdalla D.S. Minimally modified electronegative LDL and its autoantibodies in acute and chronic coronary syndromes. Clin Biochem 2006, 39:708-714.
113. Virella G., Thorpe S.R., Alderson N.L., Stephan E.M., Atchley D., Wagner F., et al. Autoimmune response to advanced glycosylation end-products of human LDL. J Lipid Res 2003, 44:487-493.
114. Lopes-Virella M.F., Virella G. Clinical significance of the humoral immune response to modified LDL. Clin Immunol 2010, 134:55-65.
115. Saad A.F., Virella G., Chassereau C., Boackle R.J., Lopes-Virella M.F. OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages. J Lipid Res 2006, 47:1975-1983.
116. Lopes-Virella M.F., Binzafar N., Rackley S., Takei A., la Via M., Virella G. The uptake of LDL-IC by human macrophages: Predominant involvement of the Fc gamma RI receptor. Atherosclerosis 1997, 135:161-170.
117. Virella G., Carter R.E., Saad A., Crosswell E.G., Game B.A., Lopes-Virella M.F. Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy. Clin Immunol 2008, 127:394-400.
118. Lopes-Virella M.F., Baker N.L., Hunt K.J., Lachin J., Nathan D., Virella G. Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes. Atherosclerosis 2011, 214:462-467.
119. Lopes-Virella M.F., Carter R.E., Baker N.L., Lachin J., Virella G. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in type 1 diabetes. Nephrol Dial Transplant 2012, 27:1416-1423.
120. Lopes-Virella M.F., Baker N.L., Hunt K.J., Lyons T.J., Jenkins A.J., Virella G. High concentrations of AGE-LDL and oxidized LDL in circulating immune complexes are associated with progression of retinopathy in type 1 diabetes. Diabetes Care 2012, 35:1333-1340.